Showing 581 - 600 results of 42,270 for search '(( 5 we decrease ) OR ( 50 ((((mg decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 0.70s Refine Results
  1. 581
  2. 582
  3. 583
  4. 584
  5. 585
  6. 586

    Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…Transgenic <i>D</i>. <i>parva</i> showed a higher carotenoid content (3.18 mg/g DW) compared with control group (2.13 mg/g DW) at 9 d. …”
  7. 587

    Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…Transgenic <i>D</i>. <i>parva</i> showed a higher carotenoid content (3.18 mg/g DW) compared with control group (2.13 mg/g DW) at 9 d. …”
  8. 588
  9. 589
  10. 590

    Demonstrates that AS-IV mitigates the injury to the lungs and colon caused by LPS. by Cheng Luo (48047)

    Published 2024
    “…<p>(A) The therapeutic impact of AS-IV in decreasing the severity of lung pathology (Bar = 10μm and 50 μm). …”
  11. 591
  12. 592
  13. 593
  14. 594

    Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF by Renée H. Fiechter (10230473)

    Published 2021
    “…</p><p>Objectives: To investigate the cellular and molecular pathways affected by IL-12p40/IL-23p40 blockade with ustekinumab in the synovium of PsA patients.</p><p>Methods: Eleven PsA patients with at least one inflamed knee or ankle joint were included in a 24-week single-center open-label study and received ustekinumab 45 mg/sc according to standard care at week 0, 4, and 16. …”
  15. 595
  16. 596

    Simulated effects of increased pCREB combined with decreased pCaMKIIα on bistability. by Yili Zhang (540283)

    Published 2022
    “…However, decreasing <i>k</i><sub><i>basalp_CaMKII</i></sub> by ~50% blocked the bistable switch (red). …”
  17. 597
  18. 598
  19. 599
  20. 600